Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)


Phase 3 Results

Eligibility Criteria

Inclusion Criteria

- Cerebral infarction except cardiac source of embolism
- Onset ≧ 1 week to ≦ 6 months before randomization
- Neurological signs persisting ≧ 1 day from onset
- Computed tomography (CT) or magnetic resonance imaging (MRI) detection of responsible site
- Age ≧ 20 years
- Systolic pressure ≦ 180 mmHg; diastolic pressure ≦ 110 mmHg

Exclusion Criteria

- Functional outcome at randomization: Modified Rankin Scale = 4, 5
- Previous or planned vascular surgery for cerebral infarction
- History of intracranial hemorrhage
- History of systemic bleeding, or other history of bleeding diathesis or coagulopathy
- Severe complications (renal or hepatic insufficiency, heart failure, hemopathy, etc.)
- Pregnant or possibly pregnant women, or nursing mothers
- History of sarpogrelate and aspirin sensitivity
- Treating malignant tumor or treated within 5 years
- Current peptic ulceration